Erelzi and Tacrolimus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Erelzi (etanercept-szzs) and Tacrolimus (tacrolimus). Common drug interactions include hepatosplenic t-cell lymphoma among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people have when they take Erelzi and Tacrolimus. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Erelzi?

Erelzi has active ingredients of etanercept-szzs. eHealthMe is studying from 11,625 Erelzi users. Check the latest studies of Erelzi.

What is Tacrolimus?

Tacrolimus has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 116,160 Tacrolimus users. Check the latest studies of Tacrolimus.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 25, 2026

31 people who take Erelzi and Tacrolimus together, and have interactions are studied.

Erelzi and Tacrolimus drug interactions.

What are the common drug interactions of Erelzi and Tacrolimus, by gender? *:

female:

Hepatosplenic t-cell lymphoma (neoplasm comprising medium-sized cytotoxic t-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow)
Hypotension (abnormally low blood pressure)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Abdominal pain upper
Hair follicle tumour benign
Pyrexia (fever)
Splenomegaly (enlargement of spleen)
Thrombocytopenia (decrease of platelets in blood)
T-cell lymphoma (a blood cell cancer)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)

male:

Abdominal pain
Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
Therapeutic response decreased (less preventive response)
Central nervous system lymphoma (cancer of central nervous system forms in lymph tissue)
Diarrhoea haemorrhagic (bloody diarrhoea)
Enteritis (inflammation of the small intestine)
Febrile neutropenia (fever with reduced white blood cells)
Propionibacterium infection
Sepsis (a severe blood infection that can lead to organ failure and death)
Transplant failure (transplantation failed to meet outcome)

What are the common drug interactions of Erelzi and Tacrolimus, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Hepatosplenic t-cell lymphoma (neoplasm comprising medium-sized cytotoxic t-cells that show a significant sinusoidal infiltration in the liver, spleen, and bone marrow)
Hypotension (abnormally low blood pressure)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Abdominal pain upper
Hair follicle tumour benign
Pyrexia (fever)
Splenomegaly (enlargement of spleen)
Thrombocytopenia (decrease of platelets in blood)
T-cell lymphoma (a blood cell cancer)
Lymphoproliferative disorder (a medical condition in which the immune system makes too many white blood cells)

20-29:

Abdominal pain
Diarrhoea
Graft versus host disease in liver (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the liver)
Graft versus host disease in skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin)
Pyrexia (fever)
Rash erythematous (redness of the skin)
Therapeutic response decreased (less preventive response)
Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)

30-39:

n/a

40-49:

Central nervous system lymphoma (cancer of central nervous system forms in lymph tissue)
Diarrhoea haemorrhagic (bloody diarrhoea)
Enteritis (inflammation of the small intestine)
Febrile neutropenia (fever with reduced white blood cells)
Propionibacterium infection
Sepsis (a severe blood infection that can lead to organ failure and death)
Transplant failure (transplantation failed to meet outcome)
Abdominal pain
Diplopia (double vision)
Gait disturbance

50-59:

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Post transplant lymphoproliferative disorder
Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell)
Lymphadenopathy (disease or enlargement of lymph nodes)
Transplant failure (transplantation failed to meet outcome)
Tumour lysis syndrome (a group of metabolic complications that can occur after treatment of cancer, these complications are caused by the breakdown products of dying cancer cells)

60+:

n/a

What are the existing conditions these people have? *

Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 13 people, 41.94%
Immunodeficiency Disorders: 8 people, 25.81%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 3 people, 9.68%
Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 2 people, 6.45%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 6.45%
Polyarteritis Nodosa (progressive disease of connective tissue): 2 people, 6.45%
Iridocyclitis (inflammation of the iris and ciliary body of the eye): 2 people, 6.45%
Hyperglycemia (high blood sugar): 2 people, 6.45%
Graft Versus Host Disease In Skin (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the skin): 2 people, 6.45%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Erelzi and Tacrolimus?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously